Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Sorli, Christopher, Dr ; Harashima, Shin-ichi, MD ; Tsoukas, George M, MD ; Unger, Jeffrey, MD ; Karsbøl, Julie Derving, MD ; Hansen, Thomas, PhD ; Bain, Stephen C, Prof

The lancet. Diabetes & endocrinology, 2017-04, Vol.5 (4), p.251-260 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível